Centre National De La Recherche Scientifique

National Institute of Health and Medical Research

Université Paris Diderot-Paris 7

Ecole Normale Superieure

Urgo Recherche Innovation Et Developpement

Inserm

Maïté Noizet

Claire Dugast-Darzacq

Xavier Darzacq

Béatrice Spiluttini Hebert

Béatrice Spiluttini HÉBERT

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologs thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologs thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.

Molecular targets for the treatment of wounds, in particular chronic wounds

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of HIC1, FOXS1, CREB5, IRF7, POU2F2, STAT4, TCF4, and/or an agent that enhances the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2.

Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids

Growing community of inventors

Versailles, France

Maïté Noizet